Large-scale public data reuse to model immunotherapy response and resistance
暂无分享,去创建一个
Peng Jiang | X. Shirley Liu | Changxin Wan | Jingxin Fu | Karen Li | Wubing Zhang | Jing Zhang | Peng Jiang | X. S. Liu | Changxin Wan | Jingxin Fu | Jing Zhang | Wubing Zhang | Karen Li | X. Liu | Peng Jiang | X. Liu
[1] K. Brown,et al. Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.
[2] E. Schmidt,et al. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. , 2019, Journal of Clinical Oncology.
[3] Henry W. Long,et al. A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.
[4] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[5] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[6] Feng Zhang,et al. Identification of essential genes for cancer immunotherapy , 2017, Nature.
[7] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[8] Ash A. Alizadeh,et al. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .
[9] John G. Doench,et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.
[10] G. Freeman,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[11] Shibing Deng,et al. OASIS: web-based platform for exploring cancer multi-omics data , 2015, Nature Methods.
[12] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..